These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27305276)

  • 1. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours.
    Roncolato FT; Chatfield M; Houghton B; Toner G; Stockler M; Thomson D; Friedlander M; Gurney H; Rosenthal M; Grimison P;
    Intern Med J; 2016 Aug; 46(8):893-8. PubMed ID: 27305276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary Function in Patients With Germ Cell Cancer Treated With Bleomycin, Etoposide, and Cisplatin.
    Lauritsen J; Kier MG; Bandak M; Mortensen MS; Thomsen FB; Mortensen J; Daugaard G
    J Clin Oncol; 2016 May; 34(13):1492-9. PubMed ID: 26903578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients.
    Comis RL; Kuppinger MS; Ginsberg SJ; Crooke ST; Gilbert R; Auchincloss JH; Prestayko AW
    Cancer Res; 1979 Dec; 39(12):5076-80. PubMed ID: 91430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
    Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC;
    Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).
    Shamash J; Sarker SJ; Huddart R; Harland S; Joffe JK; Mazhar D; Birtle A; White J; Chowdhury K; Wilson P; Marshall MR; Vinnicombe S
    Ann Oncol; 2017 Jun; 28(6):1333-1338. PubMed ID: 28327896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
    Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
    J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.
    Maruyama Y; Sadahira T; Mitsui Y; Araki M; Wada K; Tanimoto R; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
    Med Oncol; 2018 Apr; 35(6):80. PubMed ID: 29700638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of corticosteroid administration on bleomycin lung toxicity.
    Jensen JL; Goel R; Venner PM
    Cancer; 1990 Mar; 65(6):1291-7. PubMed ID: 1689606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors.
    Calaway AC; Foster RS; Adra N; Masterson TA; Albany C; Hanna NH; Einhorn LH; Cary C
    J Clin Oncol; 2018 Oct; 36(29):2950-2954. PubMed ID: 30156983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
    de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
    J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours.
    Anthoney DA; McKean MJ; Roberts JT; Hutcheon AW; Graham J; Jones W; Paul J; Kaye SB
    Br J Cancer; 2004 Feb; 90(3):601-6. PubMed ID: 14760371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity.
    Kawai K; Hinotsu S; Tomobe M; Akaza H
    Jpn J Clin Oncol; 1998 Sep; 28(9):546-50. PubMed ID: 9793027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
    Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
    Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
    Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
    J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older.
    Thomsen FB; Bandak M; Thomsen MF; Lauritsen J; Christensen IJ; Daugaard G
    Cancer; 2014 Jan; 120(1):43-51. PubMed ID: 24108413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of lung abscess during chemotherapy for testicular tumor].
    Hayashi Y; Miyago N; Takeda K; Yamaguchi Y; Nakayama M; Arai Y; Kakimoto K; Nishimura K
    Hinyokika Kiyo; 2014 May; 60(5):237-9. PubMed ID: 24894860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.